NCT00035841已完成2 期
Phase 2 Study of TLK286 in Metastatic Breast Cancer
Telik6 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2002年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 6
研究概览
简要总结
The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic diagnosis of breast cancer
- •Metastatic disease
- •Measurable or evaluable disease
- •No prior chemotherapy regimens
- •Age at least 18 years
- •Adequate liver and kidney function
- •Adequate bone marrow function
排除标准
- •Pregnant or lactating women
- •Unstable medical conditions
- •Chemotherapy within 14 days of TLK286
- •Radiation therapy within 14 days of TLK286
- •Hormonal therapy within 14 days of TLK286
- •Immunotherapy within 14 days of TLK286
- •CNS metastasis unless controlled by treatment
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast CancerMetastatic Breast CancerNCT00976365Taiwan THL Co.LTd.60
已完成
2 期
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung CancerCarcinoma, Non-small-cell LungNCT00040638Telik40
已完成
2 期
Imatinib Mesylate in Treating Patients With Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerMale Breast CancerNCT00045188National Cancer Institute (NCI)35
已完成
1 期
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung CancerCarcinoma, Non-small-cell LungNCT00047801Telik28
已完成
2 期
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa StudyBreast NeoplasmsNCT00229697AstraZeneca317